Latest News for LLY

Authoritative coverage of LLY: earnings, product launches, management updates, regulatory filings, and trusted third‑party analysis to support research and due diligence.

Quick links:Financial Metrics•Technicals•Returns•Market Cap & EV•Financials

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

reuters.com•

4 days ago

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

benzinga.com•

4 days ago

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc AFRM is a buy. “It's at $72, it's going to $100,” he noted.

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

247wallst.com•

4 days ago

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.

2 All-American Dividend Gems To Buy Before The Market Wakes Up

seekingalpha.com•

4 days ago

2 All-American Dividend Gems To Buy Before The Market Wakes Up

I see Las Vegas' struggles as a mirror of broader economic woes of high prices, low consumer confidence, and trade uncertainty, pressuring markets and creating slim margins for error. I believe market overreactions to earnings misses present opportunities. High valuations demand strong growth, but fear-driven sell-offs can uncover undervalued, high-quality stocks. I highlight two iconic American companies with strong fundamentals, offering compelling risk/reward for long-term investors seeking reliable dividend growth in a volatile market.

fool.com•

4 days ago

Why Eli Lilly Stock Popped Today

Shares of Eli Lilly (LLY 1.49%), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its stock bounce back a modest 2.5% through 1:55 p.m. ET Monday on some positive news out of Wall Street.

Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?

zacks.com•

5 days ago

Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.

Lilly (LLY) Reliance on International Sales: What Investors Need to Know

zacks.com•

5 days ago

Lilly (LLY) Reliance on International Sales: What Investors Need to Know

Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

zacks.com•

5 days ago

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

seekingalpha.com•

Aug 9, 2025

Eli Lilly: Another Not-To-Miss Dip

Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar plunge for its rival Novo Nordisk a few days ago, and also only makes for a stronger Buy case. The company's position in the weight management market remains undisputed for now; it's also reported robust financials in Q2 2025 along with upgraded guidance.